{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:51:28Z","timestamp":1783075888454,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,3,20]],"date-time":"2014-03-20T00:00:00Z","timestamp":1395273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00228-014-1664-3","type":"journal-article","created":{"date-parts":[[2014,3,19]],"date-time":"2014-03-19T01:56:03Z","timestamp":1395194163000},"page":"695-699","source":"Crossref","is-referenced-by-count":10,"title":["Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients"],"prefix":"10.1007","volume":"70","author":[{"given":"Buster","family":"Mannheimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Koukel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"\u00d6sby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Eliasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,20]]},"reference":[{"issue":"1","key":"1664_CR1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02245444","volume":"114","author":"LE Beijsterveldt van","year":"1994","unstructured":"van Beijsterveldt LE et al (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berlin) 114(1):53\u201362","journal-title":"Psychopharmacology (Berlin)"},{"issue":"4","key":"1664_CR2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199808000-00004","volume":"20","author":"OV Olesen","year":"1998","unstructured":"Olesen OV et al (1998) Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20(4):380\u2013384","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1664_CR3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s002130051171","volume":"147","author":"MG Scordo","year":"1999","unstructured":"Scordo MG et al (1999) Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berlin) 147(3):300\u2013305","journal-title":"Psychopharmacology (Berlin)"},{"issue":"1","key":"1664_CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/00912700022008702","volume":"40","author":"CL Alfaro","year":"2000","unstructured":"Alfaro CL et al (2000) CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 40(1):58\u201366","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1664_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00007691-200106000-00007","volume":"23","author":"E Spina","year":"2001","unstructured":"Spina E et al (2001) Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 23(3):223\u2013227","journal-title":"Ther Drug Monit"},{"issue":"4","key":"1664_CR6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00004714-200208000-00014","volume":"22","author":"E Spina","year":"2002","unstructured":"Spina E et al (2002) Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 22(4):419\u2013423","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1664_CR7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-2002-25026","volume":"35","author":"G Bondolfi","year":"2002","unstructured":"Bondolfi G et al (2002) The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 35(2):50\u201356","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"1664_CR8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","volume":"40","author":"J Leon","year":"2007","unstructured":"Leon J et al (2007) A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40(3):93\u2013102","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"1664_CR9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/FTD.0b013e31818679c9","volume":"30","author":"B Mannheimer","year":"2008","unstructured":"Mannheimer B et al (2008) Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Ther Drug Monit 30(5):565\u2013569","journal-title":"Ther Drug Monit"},{"issue":"7","key":"1664_CR10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-200241070-00001","volume":"41","author":"ML Dahl","year":"2002","unstructured":"Dahl ML (2002) Cytochrome p450 phenotyping\/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41(7):453\u2013470","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1664_CR11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1345\/aph.1R333","volume":"47","author":"AL Cartwright","year":"2013","unstructured":"Cartwright AL et al (2013) Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms. Ann Pharmacother 47(3):350\u2013360","journal-title":"Ann Pharmacother"},{"issue":"2","key":"1664_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/pgs.12.201","volume":"14","author":"A Llerena","year":"2013","unstructured":"Llerena A et al (2013) Pharmacogenetics of clinical response to risperidone. Pharmacogenomics 14(2):177\u2013194","journal-title":"Pharmacogenomics"},{"issue":"1","key":"1664_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tpj.2010.73","volume":"11","author":"N Fleeman","year":"2011","unstructured":"Fleeman N et al (2011) Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 11(1):1\u201314","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"1664_CR14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","volume":"116","author":"M Ingelman-Sundberg","year":"2007","unstructured":"Ingelman-Sundberg M et al (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116(3):496\u2013526","journal-title":"Pharmacol Ther"},{"issue":"6","key":"1664_CR15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/sj.clpt.6100188","volume":"81","author":"F Sjoqvist","year":"2007","unstructured":"Sjoqvist F, Eliasson E (2007) The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 81(6):899\u2013902","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1664_CR16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","volume":"66","author":"R Ghotbi","year":"2010","unstructured":"Ghotbi R et al (2010) Carriers of the UGT1A4 142\u00a0T\u2009>\u2009G gene variant are predisposed to reduced olanzapine exposure\u2013an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 66(5):465\u2013474","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1664_CR17","first-page":"284","volume":"60","author":"C Sachse","year":"1997","unstructured":"Sachse C et al (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60(2):284\u2013295","journal-title":"Am J Hum Genet"},{"key":"1664_CR18","unstructured":"Flockhart, D., Drug interactions: Cytochrome P450 Drug Interaction Table. Indiana School of Medicine 2007. Available at: http:\/\/medicine.iupui.edu\/flockhart\/table.htm Accessed August 28, 2013."},{"issue":"1","key":"1664_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-199402000-00001","volume":"16","author":"M Jerling","year":"1994","unstructured":"Jerling M, Bertilsson L, Sjoqvist F (1994) The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 16(1):1\u201312","journal-title":"Ther Drug Monit"},{"issue":"4","key":"1664_CR20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00007691-199508000-00003","volume":"17","author":"N Yasui","year":"1995","unstructured":"Yasui N et al (1995) Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 17(4):333\u2013335","journal-title":"Ther Drug Monit"},{"issue":"8","key":"1664_CR21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1553-2712.1997.tb03793.x","volume":"4","author":"M Grzybowski","year":"1997","unstructured":"Grzybowski M, Younger JG (1997) Statistical methodology: III. Receiver operating characteristic (ROC) curves. Acad Emerg Med 4(8):818\u2013826","journal-title":"Acad Emerg Med"},{"issue":"20","key":"1664_CR22","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1002\/sim.1228","volume":"21","author":"D Faraggi","year":"2002","unstructured":"Faraggi D, Reiser B (2002) Estimation of the area under the ROC curve. Stat Med 21(20):3093\u20133106","journal-title":"Stat Med"},{"issue":"21","key":"1664_CR23","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","volume":"352","author":"GR Wilkinson","year":"2005","unstructured":"Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352(21):2211\u20132221","journal-title":"N Engl J Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1664-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1664-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1664-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:49:07Z","timestamp":1558702147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1664-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,20]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["1664"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1664-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,20]]}}}